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1. Introduction  
Changes in lipid profile, like increased serum triglycerides (TG) and decreased cholesterol 
levels have been described in patients with HIV infection before the introduction of highly 
active antiretroviral therapy (HAART) (Constans et al., 1994; Grunfeld et al., 1991; Shor-Posner 
et al., 1993). However, with the widespread use of HAART it has been worsening. After the 
introduction of protease inhibitors (PIs) in 1996, patients developed a syndrome of fat 
redistribution with peripheral loss and central gain, generally associated with metabolic 
abnormalities and insulin resistance (lipodistrophy syndrome) (Carr et al., 1998). High levels 
of TG and total cholesterol (TC) concentrations are well known and often associated with 
abnormal body fat distribution and glucose metabolism disturbs (Carr et al., 1998). On persons 
treated with HAART, TG and TC elevations are associated with the use of protease 
inhibitors/nonnucleoside reverse transcriptase inhibitor (PIs/NNRTI) regimens (54 and 44% 
respectively), followed by PIs regimes (40 and 27% respectively) and NNRTI-containing 
combinations (32 and 23% respectively) (Friss Moller et al., 2003). All these symptoms are 
related to metabolic syndrome that could act to increase the cardiovascular risk in HIV-
infected patients. Another aspect of these metabolic alterations is non-alcoholic fatty liver 
disease. Its prevalence is higher in HIV infected patients (30-40%) than in general population 
(14-31%) (Crum-Cianflone et al., 2009; Guaraldi et al., 2008). It is believed that there is a 
potential role of the antiretroviral therapy in the pathology of non-alcoholic fatty liver disease 
due to its negative effects on glucose control, lipid metabolism, body fat redistribution, insulin 
resistance and mitochondrial toxicity (Crum-Cianflone et al., 2009; Guaraldi et al., 2008). 
HAART has change dramatically the natural history of HIV-infection, leading to a notable 
extension of life expectancy and decline in mortality (Palella et al., 1998). Thus, mortality 
rates in HIV-infected patients who have experienced a CD4 recovery (> 500 cells/mm3) on 
long-term treatment resemble that of the general population (Lewden et al., 2007). However, 
prolonged metabolic imbalances could act on the long-term prognosis and outcome of HIV-
infected persons. There is an increasing concern about the cardiovascular risk in this 
population despite the virological control (Graham, et al., 2000; Manfredi et al., 2000; Palella 
et al., 1998). Cardiovascular disease is emerging as one of the most important co morbidity 
and cause of death (Sackoff et al., 2006). Early identification and proper management of 
traditional cardiovascular risk factors, such as smoking, overweight or hypertension is 
imperative (Barbaro, 2006; Triant et al., 2007). As the prevalence of metabolic disorders is 
age-related their incidence will increase as HIV population becomes older (Triant et L., 
2007). Thus, active prevention, together with prompt diagnosis and management of 
cardiovascular risk factors must be integrated on the routine of HIV care.  
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2. Dyslipidemia and antiretroviral therapy 
The degree of dyslipidemia and lipid changes is different among the several classes of 
antiretroviral drugs and even among the individual drugs within each class. Furthermore, 
the magnitude of lipid changes varies widely among patients on the same antiretroviral 
regimen, reflecting the likely important role of host genomics. While the PI and NNRTI have 
well-described effects on lipids, there have been no reported significant changes in lipid 
profiles or cardiovascular risk associated with the new classes of antiretroviral such as, 
fusion inhibitors (enfuvirtide), CC chemokine receptor type 5 (CCR5) receptor inhibitors 
(maraviroc) or integrase inhibitors (raltegravir) as described in table 1. Nonnucleoside 
reverse transcriptase inhibitors are also associated with lipid abnormalities, but to a lesser 
extent than PIs. Nucleoside reverse transcriptase inhibitors have been associated with 
mitochondrial toxicity and insulin resistance, but the lipid changes associated with them are 
normally less significant than those caused by PI or NNRTIs (Malvestutto & Aberg, 2010, 
Hammond et al., 2004). 
 
PI Lipid Change 
Atazanavir No change 
Atazanavir/ritonavir ↑ LDL-c. TG and no change HDL-c 
Darunavir/ritonavir ↑ TC, LDL-c, TG and no change HDL-c 
Fosamprenavir/ritonavir ↑ TC, LDL-c, TG and no change HDL-c 
Indinavir ↑ TC, LDL-c, TG and  
Lopinavir/ritonavir ↑ TC, LDL-c, TG and no change HDL-c 
Nelfinavir ↑ TC, LDL-c, TG and no change HDL-c 
Ritonavir ↑ TC, LDL-c, TG and  HDL 
Saquinavir/ritonavir ↑ TC, LDL-c, TG and no change HDL-c 
Tipranavir/ritonavir ↑ TC, LDL-c, TG and not known in HDL-c 
ITRN  
Stavudine ↑ TG  
ITRNN  
Efavirenz ↑ TC, LDL-c, TG and HDL-c 
Nevirapine ↑ TC, LDL-c, TG and HDL-c 
Etravirine No change 
Integrase Inhibitor  
Raltegravir No change 
Fusion Inhibitor  
Enfuvirtude No change 
CC Chemokine receptor  
Maraviroc No change 
Table 1. Lipid changes with antiretroviral therapy. 
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3. Cardiovascular risk evaluation 
Primary prevention must be indicated and periodic assessment could be done every 3-6 
months in HIV-infected person on treatment and annually in patients not treated (Blanco et 
al., 2010). Factors to be evaluated include: age, smoking habit, diet, physical activity, alcohol 
consumption, personal and family history of coronary heart disease, hyperlipidemia, 
diabetes mellitus and hypertension (Adult Treatment Panel III, 2002). In women, the 
menopausal status is relevant. Baseline blood pressure, body mass index and waist 
circumference should be recorded together with lipid profile, glucose and renal function 
(Blanco et al., 2010). In addition, virologic control with HAART use may also decrease the 
risk of noninfectious co morbidities including cardiovascular disease.  
To predict the cardiovascular risk, Framingham Risk Score could be use (Anderson et al., 
1991). Using this score, which includes: age, gender, TC, HDL-c, systolic blood pressure and 
smoking, an individual could be stratified into three risk categories: low (<10%), medium 
(10-20%) and high risk (> 20%) in 10 year. The extent to which this model could be used 
from the general population to HIV-infected people is still under discussion. The 
Framingham Risk Score has not been specifically validated for HIV-infected subjects and 
factors related to the HIV/AIDS could not be adequately evaluated, but until more evidence 
is available, management strategies for cardiovascular risk proposed for the general 
population could be applied to HIV-infected subjects. In the D:A:D study (Data Collection 
on Adverse events of Anti-HIV Drugs), myocardial infarction rates seen in HIV-infected 
person treated and untreated were higher and lower respectively, than those predicted with 
Framingham Risk Score. Nevertheless, it predicted cardiovascular events at increased rates 
in parallel with time exposure to antiretroviral treatment (Friss-Moller et al., 2003). 
According to these findings, Framingham Risk Score may be useful for an initial estimation 
of cardiovascular risk in HIV-infected persons, although a more accurate model needs to be 
developed. 
To contribute with the discussion about HIV and cardiovascular risk, it was recently 
showed by the Kaiser Permanent Members that HIV infection confers a high independent 
risk for coronary heart disease (Klein et al., 2011). They matched HIV-infected adults of 
Kaiser Permanent California health plan with HIV negative members (1:10 ratio) on age, sex, 
medical center and start year follow-up. The cohort was followed from first Kaiser 
Permanent enrollment in 1996 until the end of December 2008. Coronary heart disease rates 
among HIV-infected members stratified by antiretroviral use and the most recent and 
lowest CD4 cell counts recorded were compared with rates among HIV negative members- 
Adjusted rate ratios (RRs) for any CHD diagnosis and for MIs were obtained from Poisson 
regression models adjusting for age, sex, race, tobacco use, alcohol/drug abuse, obesity, 
diabetes, and use of lipid lowering and hypertension therapy. 20,775 HIV-infected and 
215,158 HIV negative members contributed to 90,961 and 1,133,333 persons-years (py) 
respectively. HIV-infected and not infected individuals had respectively 399 (447/100,00 py) 
and 3,463 (311/100,00 py) coronary heart disease events and 248 and 1,825 myocardial 
infarction. In the HIV-infected group, the only significant HIV-related factor associated with 
an increased risk of coronary heart disease was the lowest CD4 ≤ 200 cells/mm3 recorded 
(relative risk = 1.3 [95% CI: 10.-1.6, p = 0,022) (Klein et al., 2011). HIV-infected patients on 
antiretroviral therapy and with CD4 count > 500 cells/mm3 (recent or lowest) had similar 
coronary heart disease risk compared with HIV negative group. These findings support 
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early initiation of antiretroviral therapy and aggressive management of cardiovascular 
disease risk. 
Nowadays, the recommendations suggest that HIV-infected people undergo evaluation and 
treatment on the basis of the Third National Cholesterol Education Program (ATP III) for 
dyslipidemia (Adult Treatment Panel III, 2002). Lipoprotein profiles should be done with at 
least 9 to 12 hours of fasting (Adult Treatment Panel III, 2002). Dyslipidemia is defined as 
TC ≥ 200 mg/dL, LDL-c ≥ 130 mg/dL, TG ≥ 150 mg/dL, HDL-c < 40 mg/dL and TC/HDL ≥ 
6.5. Therapeutic indications are made regarding the time for initiating specific lifestyle 
modifications and prescription of lipid-lowering therapy in order to achieve LDL-c goals 
(Adult Treatment Panel III, 2002). As for the general population, distinct drugs are 
suggested regarding the lipid alterations: hypercholesterolemia and/or 
hypertriglyceridemia. An update from ATP III (Grundy et al., 2004) included diabetes in 
high risk category for cardiovascular risk, and there is an additional benefit adding LDL-
lowering therapy in this population.  
4. Lifestyle interventions 
Counseling on healthy diet habits, regular exercise, alcohol consumption and quitting 
smoking should be the first step to decrease cardiovascular risk. Hyperglycemia due to 
diabetes mellitus must be managed aggressively, with consideration of treatment with 
insulin sensitizers, such as metformin and thiazolidenediones when appropriate (Kalra et 
al., 2011). 
Smoking is one well-know modifiable risk factor for coronary heart disease and its cessation 
leads to a decrease in cardiovascular and malignances risk (Mohiuddin et al., 2007). The 
smoking prevalence in HIV-infected patients is generally high, around 45-70%, much more 
than observed in uninfected controls (Friss-Moller et al., 2003; Mamary et al., 2002; Saves et 
al., 2003). Smoking cessation should be a priority in managing cardiovascular risk in HIV-
infected persons. 
The prevalence of hypertension in HIV-infected patients is around 25% (Glass et al., 2006; 
Jung et al., 2004,). The current recommendations for general population should be followed 
for HIV-infected patients, considering drug-interactions between antiretroviral drugs and 
antihypertensive drugs, particularly calcium-channel blockers. The management of 
hypertension should include lifestyle modifications such as weight loss if needed, 
incorporating low total and saturated fat in the diet, reduction of dietary sodium to 2.5 
g/day, aerobic exercise and decreasing alcohol consumption (Malvestutto & Aberg, 2010). 
Diet and exercise could help improve dyslipidemia, high blood pressure and glucose 
metabolism (Barrios et al., 2002; Fitch et al., 2006). Comprehensive dietary interventions 
have been demonstrated to decrease LDL-c by 20% in short term interventions in which 
adherence is maximal (Jenkins et al., 2003; Skeaff et al., 2005). The majority of the cholesterol 
lowering effect may be achieved by substituting unsaturated fats for saturated fats and 
increasing intake of plant sterols to at least 1.5 g/day. Each strategy could decrease the 
levels of LDL-c around 10% (Clifton et al., 2009). Further cholesterol lowering is also 
possible through weight loss and increasing intake of soluble fiber and soy protein (Clifton 
et al., 2009). Replacing saturated and trans fats with unsaturated fats is therefore a key 
strategy for lowering serum LDL-c (Clifton et al., 2009). Weight loss in those who are 
overweight lowers serum TC, LDL-c and TG and increases HDL-c (Datillo & Kris-Etherton, 
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1992). Weight reduction should be strongly encouraged if obesity is present. There are 
several dietary components that may be protective against cardiovascular disease through 
known and unknown mechanisms and their consumption may be encouraged as part of a 
cholesterol lowering and cardiovascular protective diet such as fish oil, whole grains, fruit, 
vegetables and nuts. Low intake of alcohol may also be advised (Cheng et al., 2004; Clifton 
et al., 2009). 
Clinicians should be alert for potential exacerbating conditions, such as hypothyroidism, 
renal and liver disease and hypogonadism. They should also consider the effects of 
glucocorticoids, beta-blockers, thiazide diuretics, thyroid preparations and hormonal agents 
(such as androgens, progestins, and estrogens) on both cholesterol and triglyceride levels 
(Dube et al., 2003). 
5. Lipid lowering therapy for HIV-infected patients 
The benefits of lipid-lowering therapy interventions have been extended to HIV-infected 
persons. Enthusiasm for drug therapy for dyslipidemia should be tempered with the 
understanding that interventions for advanced immunosuppression, opportunistic 
infections, malignancies, and HIV-associated wasting, should be done during the initial 
stages of treatment. There is currently no basis for a more aggressive dyslipidemia 
intervention among HIV-infected patients than what is currently recommended for the 
general population. Due to a significant possibility for drug interaction between some lipid-
lowering agents and antiretroviral drugs, special attention should be given to the choice of 
lipid-lowering therapy (Dube et al., 2003). Some advises should be instituted before 
pharmacological interventions as explained in life style modification section, except when 
there is an urgent need to prompt treatment (individuals with high risk for cardiovascular 
disease or with previous coronary heart disease or diabetes mellitus) (Adult Treatment 
Panel III, 2002).  
5.1 Statins 
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase enzyme catalyzes the 
first step of cholesterol synthesis in the mevalonate pathway. Statins lower LDL-c levels 
through the inhibition of this specific enzyme. The more potent statins have been shown to 
reduce LDL-c levels by up to 55%. In addition, they also decrease TG levels to a lesser extent 
(up to 20%), probably through the inhibition of its synthesis in the liver and increase of 
lipoprotein lipase enzyme activity in the adipocytes (Jones et al., 2003; Saiki et al., 2005). 
Furthermore, statins are known to modestly increase levels of HDL-c (up to 10%). The 
precise mechanism by which statins increase HDL-c levels is not known; however, it is 
thought to result from apolipoprotein A1 gene induction through the activation of 
peroxisome proliferator activated receptors (Yano et al., 2007). It is also postulated that 
statins have pleiotropic effects, (certain lipid-independent effects) that contribute to some 
degree to their antiatherothrombotic properties. Among the proposed mechanisms are 
modulation of inflammatory response, improvement of endothelial function and inhibition 
of coagulation factors (Ray & Cannon, 2005). 
Lovastatin and simvastatin are highly metabolized through the cytrocrome P450 (CYP3A4), 
which is inhibited by most PIs. Thus, their concomitant use is contraindicated to avoid 
serious side effects of statins overexposure such as rhabdomyolysis. Pravastatin and 
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fluvastatin appear to be safe for use in association with HAART (Dube et al., 2003). 
Pravastatin is eliminated mostly by glucoronidation, fluvastatin by CYP 2C9 isoform, and 
CYP 3A4 has no role in their metabolism (Willians & Feely, 2002). Table 2 has a summary of 
the lipid lowering therapy in HIV infected people. 
Rosuvastatin and atorvastatin have higher efficacy than pravastatin in decreasing LDL-c. 
Due to partial metabolism of atorvastatin by CYP3A4, it must be used with caution when 
co administered with a PI, with hepatitis and myositis being potential toxicities. 
Rosuvastatin is the most potent statin to reduce LDL-c and TG, with serum levels being 
only slightly modified when co administered with a PI (Aslangui et al., 2010; Calza et al., 
2008). It can also reduce TG and increase HDL-c. Moreover, pharmacokinetic studies have 
demonstrated that its metabolism is not dependent on the CYP 450 3A4 isoenzyme and its 
use could be considered in PI-treated individuals since the risk of drug-drug interactions 
are low (Martin et al., 2003). Only 10% of the administered dose is metabolized by CYP 
2C9 isoenzyme into N-desmethyl rosuvastatin and its metabolite are 90% eliminated by 
the fecal route (Cheng, 2004; Martin et al., 2003; Willians & Feely, 2002). The usual 
recommended starting dose of rosuvastatin is 10 mg daily, but initiation at 5 mg daily 
may be considered for patients who have predisposing factors for myopathy or are taking 
cysclosporine. In subjects with severe renal impairment or taking fibrates, therapy with 
rosuvastatin should be used with great caution, daily dose should be initiated at 5 mg and 
not exceed 10 mg (Cheng, 2004). 
Until recently, pravastin and rosuvastatin were thought to be safer than other statins 
because their metabolism do not utilize the CYP450 3A4 enzyme system influenced by many 
antiretroviral medications. However, recent studies have demonstrated increased plasma 
levels (expressed as area under the plasma concentration-time curve [AUC] and maximum 
concentration [Cmax] values) of these statins as a result of exposure to certain antiretroviral 
drugs (Busti et al., 2008; Calza et al., 2005; Mazza et al., 2008; Townsend et al., 2007).These 
increased levels may be the result of inhibition of the organic anion transporting 
polypeptide (OATP) 1B1 that facilitates statin uptake into the liver (Ray, 2009). The 
disposition of pravastatin and rosuvastatin may be more dependent than other statins on 
OATPB1B1. In agreement with this theory, a study showed that atazanavir/ritonavir was 
associated with an increased in rosuvastatin levels. This finding led the authors to conclude 
that the maximum rosuvastatin dose with atazanavir/ritonavir should be 10-20 mg, similar 
to current recommendation of a maximum rosuvastatin dose of 10 mg when used with 
lopinavir-ritonavir (Busti et al., 2008). Although increased statins levels may enhance the 
effectiveness of these drugs, this benefit may come at the expense of an increase in toxicity. 
To date there is no known interactions between rosuvastatin and NNRTIs (Ray, 2009). 
Rosuvastatin may be a particularly good option in the setting of NNRTI-based therapy, 
given its greater effectiveness and lack of proven interactions, although additional 
pharmacokinetic studies would be useful (Ray, 2009).  
Statins should be initiated at the lowest dose established for each agent. Subsequent, 
adjustments of dosing can be done according to response, and potential side effects must be 
closely monitored during follow-up, especially elevations in creatine phosphokinase and 
abnormal liver parameters (Blanco et al., 2010). Statins may improve abnormal baseline 
transaminases levels in patients with steatohepatitis (Millazo et al., 2007). Although the 
mechanism is not well defined, the removal of the lipids from the liver by statins might 
explain their benefits on liver function.  
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Goal Lipid lowering therapy 
Elevated LDL-c or non-HDL 
cholesterol with triglycerides level 
of 200-500 mg/dL 
Statins: 
- Pravastatin: 10-40 mg daily 
 
- Atorvastatin: 10-40 mg/daily 
 
- Fluvastatin: 20-40 mg/daily 
 
- Rosuvastatin 5-20 mg 
 
- Lovastatin - not recommended with PI 
 
- Simvastatin - not recommended with PI 
 
- Ezetimibe: 10 mg daily 
Triglycerides level > 500 mg/dL Fibrates and Fish Oil: 
 
- Gemfibrozil: 1200 mg daily 
 
- Fenofibrate: 200 mg daily 
 
- Omega-3 polyunsaturated fatty acids/fish 
oil: 3-5g (alternative treatment) 
Adapted from Bader & & Kelly, 2008; Bennet et al., 2007; Calza et al., 2003; Soler et al., 2006; Stebbing et 
al., 2009. 
Table 2. Lipid lowering therapy for HIV-infected people. 
5.2 Fibrates 
For patients with triglycerides > 500 mg/dL, fibrates may be the first choice, especially in 
order to prevent pancreatitis (Dube et al., 2003). When extreme elevations are present (>1000 
mg/dL in persons with a history of pancreatitis), it is reasonable to institute both drug and 
nondrug therapies concomitantly (Dube et al., 2003). Fibrates are metabolized by CYP4A, 
and there is less issue of interactions with antiretroviral drugs. They exert their effects by 
activating PPAR- ɤ. These drugs reduce plasma TG between 30% to 50%, and raise the level 
of HDL-c by 2% to 20%. Their effect on LDL-c is variable, ranging from a small decrease 
around 10% to no change or even a slight increase (Barter & Rye, 2006).  
Gemfibrozil is generally initially recommended due to its efficacy in reducing TG. When 
concomitant hypercholesterolemia is present, statins can be added to fibrates, but the risk of 
rabdomimyolysis should be closely monitored (Henry et al., 1998). Clinicians treating HIV-
infected patients must be aware of the interaction between Lopinavir/ritonavir and 
Gemfibrozil. Lopinavir/ritonavir decreases the systemic exposure to gemfibrozil by 
reducing the absorption of this drug (Busse et al., 2009). Fenofibrate is recommended by 
current guidelines for hypertrigliceridemia in antiretroviral treated patients. (Dube et al., 
2003). Fenofibrate, could decrease triglyceride levels in HIV-infected persons on 
antiretroviral therapy, but only moderately (Aberg et al., 2005).  
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5.3 Niacin 
Niacin has also been used in HIV-infected persons to improve lipid profiles. In the AIDS 
Clinical Trials Group study A5148, hyperlipidemia was treated with long-acting niacin 
during 48 weeks. Treatment resulted in significant improvements in TG, TC, HDL-c, and 
LDL-c, but a transient worsening in insulin sensitivity was also observed (Dube et al., 2006). 
The use of niacin with antiretroviral drugs may reduce the effect of niacin (Martinez et al., 
2008). Patients treated with niacin should have regular evaluation of fasting glucose levels, 
and a standard 75-g, 2-h oral glucose-tolerance test should be considered, particularly when 
lipodystrophy or traditional risk factors for type 2 diabetes mellitus are present (Dube, 2000; 
Schambelan et al., 2002). 
5.4 Fish oils  
The metabolic effects of N-3 polyunsaturated fatty acids (PUFAs) derived from marine 
sources (known as “fish oils”) have been demonstrated to reduce fasting and postprandial 
triglycerides levels in individuals without HIV infection (Simons et al., 1985). Omega-3 is 
considered an alternative treatment in non-HIV infected populations. It has been reported 
that 3-5 g per day of omega-3 fatty acids can reduce triglycerides by 30-50%, thereby 
potentially minimizing the risk of coronary heart disease and pancreatitis (O’Keefe & Harris, 
2000). Treatment with fish oil is well tolerated, although potential effects on platelets must 
be checked, especially in persons taking drugs that may favor bleeding (Gerber et al., 2009). 
5.5 Ezetimibe  
Ezetimibe is the first lipid-lowering drug that inhibits intestinal uptake of dietary and biliary 
cholesterol at the brush border of the intestine, resulting in a reduction of hepatic cholesterol 
stores and an increase in clearance of cholesterol form in the blood (Kosoglou et al., 2005). It 
doesn’t affect the absorption of fat-soluble nutrients and is an attractive option for HIV-
infected patients because it lacks CYP P450 metabolism and therefore is not expected to 
interact with antiretroviral drugs (Kosoglou et al., 2005; Negredo et al., 2006]. The major 
metabolic pathway for Ezetimibe is the glucuronidation of 4-hydroxyphenyl group by 
uridine 5’-diphosphate-glucuronosyltransferase isoenzymes to form ezetimibe-glucuronide 
in the intestine and liver (Kosoglou et al., 2005). It reduces cholesterol absorption in the 
duodenum by approximately 50%, thereby attaining reductions in LDL-c of 20% (Gagne et 
al., 2002). This benefit is significantly greater when it is associated with any of the statins, 
achieving reductions in LDL-c of up to 50% (Bennett et al., 2007; Gagne et al., 2002, Pearson 
et al., 2005,). This synergistic effect of the two drugs in combination results from the 
inhibition of duodenal cholesterol absorption by ezetimibe, together with the reduction of 
hepatic cholesterol production by statins (Kosoglou et al., 2005). The recommended dose is 
10 mg/day, and can be administered in the morning or evening with or without food 
(Kosoglou et al., 2005). 
Ezetimibe has a favorable drug-drug interaction profile. It does not have significant effects 
on plasma levels of statins (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, 
rosuvastatin, simvastatin), fibric acid derivatives (gemfibrozil, fenofibrate), digoxin, 
glipizide, warfarin and triphasic oral contraceptives (ethinylestradiol and levonorgestrel). 
Concomitant administration of food, antiacids, cimetidine or statins had no significant effect 
on ezetimibe bioavailability (Kosoglou et al., 2005). For this reason, it could be 
recommended as a second line therapy for dyslipidemia associated with antiretroviral drug 
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use if hypercholesterolemia is refractory to statins or if patient does not tolerate statins. Its 
high tolerability and the lack of interactions with the CYP 3A4 indicate that ezetimibe will 
not increase the risk of toxicity or pharmacokinetic interactions with the use of antiretroviral 
medications. In HIV-infected patients ezetimibe results in a significant decrease in LDL-c, 
without significant changes in TG (Berg-Wolf et al., 2008; Chow et al., 2009). Creatine 
phosphokinase levels should be monitored due to potential risk of rhabdomyolisis.  
Reductions in lipid levels with lipid-lowering therapy are greater in non-HIV infected 
patients than in HIV positive subjects (Martinez et al., 2008; Silverberg et al., 2009). Many 
studies that evaluated the effect of statins for the treatment of antiretroviral-associated 
dyslipidemia have shown only partial responses to such therapy, with total and LDL-c 
values being reduced by about 25% (Calza et al., 2003; Silverberg et al., 2009). The 
effectiveness and toxicity of statins among HIV-infected individuals may differ from those 
of the general population for several reasons. The patterns of dyslipidemia commonly seen 
among HIV-infected individuals are different from those observed in the general population 
(Riddler et al., 2003) and may be less responsive to treatment (Silverberg et al., 2009). 
Second, drug interactions between statins and antiretroviral drugs may impact the 
metabolism, effectiveness and toxicity associated with various forms of statins (Aberg et al., 
2006; Gerber et al., 2005; Kiser et al., 2008, Ray, 2009). Response to any lipid lowering 
therapy must be evaluated after 3-6 months by repeating a fasting lipid profile. 
6. Conclusion 
Metabolic alterations and traditional cardiovascular risk factors are common in HIV-infected 
patients. Due to the success of antiretroviral therapy in the last years in reducing AIDS 
events and mortality, the population is aging and naturally the risk of cardiovascular 
disease increases. Early detection and management of cardiovascular risk factors is 
necessary to prevent coronary heart disease. All HIV-infected patients should have their 
fasting plasma lipid profile prior to starting antiretroviral treatment and then at every three 
or four months regularly. Efforts should be done including incorporating healthy diet 
habits, regular exercise, decrease alcohol consumption and smoking cessation prior to start 
of pharmacological interventions, to avoid excess medication and undesirable side effects. 
Virologic control and immune recovery should be the first priority in the management of 
HIV-infected patients due to their associations with high mortality.  
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Human immunodeficiency virus (HIV) infection is a complex illness affecting the immune system. Acquired
immunodeficiency syndrome (AIDS) is an advanced form of HIV infection in which the patient has developed
opportunistic infections or certain types of cancer and/or the CD4+ T cell count has dropped below 200/µL.
More than 40 million persons around the world are infected with HIV, with approximately 14,000 new infections
every day. The disease causes 3 million deaths worldwide each year, 95% of them in developing countries.
Optimal management of human immunodeficiency virus requires strict adherence to highly active antiretroviral
treatment (HAART) regimens, but the complexity of these regimens (e.g., pill burden, food requirements, drug
interactions, and severe adverse effects) limits effective treatment. However, more patients with HIV are
surviving longer today because of these drugs. This allows further study of commonly associated adverse
effects. These may affect all body systems and range from serious toxicities to uncomfortable but manageable
events. This book reviews some of HAART-related metabolic and neurological complications.
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